Jay Pravin Patel1,2, Eric Hweegeun Lee1,2, Carlos Ignacio Mena-Hurtado3, Charles N Walker4. 1. Yale School of Medicine, PO Box 208058, New Haven, CT, 06520-8058, USA. 2. Yale School of Management, New Haven, CT, USA. 3. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. 4. , Fairfield, CT, USA. charles.walker@yale.edu.
Abstract
PURPOSE OF REVIEW: The prevalence of hypertension and erectile dysfunction has steadily increased, and greater than 40% of men with erectile dysfunction concurrently share a diagnosis of hypertension. The treatment of the patient with both diseases poses a clinical challenge as both are closely correlated and share multiple overlapping risk factors.To address the recognized knowledge gap among clinicians who care for these patients, we will review the current literature on the diagnosis and treatment of erectile dysfunction in the hypertensive patient and will provide recommendations for the management of this challenging patient population. RECENT FINDINGS: The pharmacological treatment of hypertension may adversely affect sexual function, and certain treatments for erectile dysfunction are contraindicated or cautioned against with certain antihypertensive agents. In review of the literature, we find that the clinician should opt to use an angiotensin-receptor blocker followed by an angiotensin-converting enzyme inhibitor or calcium channel blocker for the treatment of hypertension in patients with erectile dysfunction. Other agents require careful consideration for adverse effects on sexual function. Men with erectile dysfunction should be assessed for cardiovascular fitness for sexual activity, and PDE-5 inhibitors remain the first-line treatment for erectile dysfunction.
PURPOSE OF REVIEW: The prevalence of hypertension and erectile dysfunction has steadily increased, and greater than 40% of men with erectile dysfunction concurrently share a diagnosis of hypertension. The treatment of the patient with both diseases poses a clinical challenge as both are closely correlated and share multiple overlapping risk factors.To address the recognized knowledge gap among clinicians who care for these patients, we will review the current literature on the diagnosis and treatment of erectile dysfunction in the hypertensivepatient and will provide recommendations for the management of this challenging patient population. RECENT FINDINGS: The pharmacological treatment of hypertension may adversely affect sexual function, and certain treatments for erectile dysfunction are contraindicated or cautioned against with certain antihypertensive agents. In review of the literature, we find that the clinician should opt to use an angiotensin-receptor blocker followed by an angiotensin-converting enzyme inhibitor or calcium channel blocker for the treatment of hypertension in patients with erectile dysfunction. Other agents require careful consideration for adverse effects on sexual function. Men with erectile dysfunction should be assessed for cardiovascular fitness for sexual activity, and PDE-5 inhibitors remain the first-line treatment for erectile dysfunction.
Authors: Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal Journal: JAMA Date: 2006-04-05 Impact factor: 56.272
Authors: Marie A Krousel-Wood; Paul Muntner; Tareq Islam; Donald E Morisky; Larry S Webber Journal: Med Clin North Am Date: 2009-05 Impact factor: 5.456
Authors: Francisco J Mena-Martin; Juan C Martin-Escudero; Fernando Simal-Blanco; Jose L Carretero-Ares; Delfin Arzua-Mouronte; Vicente Herreros-Fernandez Journal: J Hypertens Date: 2003-07 Impact factor: 4.844
Authors: Robert A Kloner; John B Kostis; Thomas P McGraw; Chunfu Qiu; Alankar Gupta Journal: J Clin Hypertens (Greenwich) Date: 2022-01-31 Impact factor: 2.885